Risk factors for hepatitis B in an outbreak of hepatitis B and D among injection drug users

During January–April, 2000, 12 cases of acute hepatitis B were reported in Pierce County, Washington, compared with seven in all of 1999. Seven (58.3%) case patients were injection drug users (IDUs), three of whom were coinfected with hepatitis D virus (HDV) and died of fulminant hepatitis. Vaccination clinics were implemented at the local health department and needle exchange program to control the outbreak. We investigated this outbreak to determine risk factors for hepatitis B virus (HBV) transmission among IDUs. Hepatitis B cases were ascertained through routine surveillance and prevaccination testing at vaccination clinics. We conducted a case-control study comparing IDU case patients with HBV-susceptible IDUs identified at the vaccination clinics. Fifty-eight case patients were identified during January–December, 2000, 20 (34.5%) of whom were coinfected with HDV. Thirty-eight case patients (65.5%) reported current IDU. In the case-control study, the 17 case patients were more likely than the 141 controls to report having more than one sex partner [odds ratio (OR)=4.8, 95% confidence interval (CI)=1.5–15.0], injecting more than four times a day (OR=4.5, 95% CI=1.2–15.6) and sharing drug cookers with more than two people (58.8% vs. 14.0%, OR=14.0, 95% CI=2.4–81.5). Results were similar after controlling for syringe sharing in multivariable analysis. IDUs should be vaccinated against hepatitis B and should be advised against sharing drug injection equipment.

[1]  Holly Hagan,et al.  Using a jail-based survey to monitor HIV and risk behaviors among seattle area injection drug users , 2001, Journal of Urban Health.

[2]  H. Hagan,et al.  Changes in injection risk behavior associated with participation in the seattle needle-exchange program , 2000, Journal of Urban Health.

[3]  R. Garfein,et al.  Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. , 2002, American journal of epidemiology.

[4]  M. Gwinn,et al.  Age-specific seroprevalence of HIV, hepatitis B virus, and hepatitis C virus infection among injection drug users admitted to drug treatment in 6 US cities. , 2002, American journal of public health.

[5]  M. Bellis,et al.  Predictors of hepatitis B and C infection in injecting drug users both in and out of drug treatment. , 2001, Addiction.

[6]  S. Hadler,et al.  Characterization of hepatitis D virus genotype III among Yucpa Indians in Venezuela. , 2001, The Journal of general virology.

[7]  P. Kerndt,et al.  Prevalence of HIV and hepatitis B and self-reported injection risk behavior during detention among street-recruited injection drug users in Los Angeles County, 1994-1996. , 2001, Addiction.

[8]  M. Tannahill,et al.  An outbreak of acute hepatitis B infection among injecting drug users in Inverclyde, Scotland. , 2001, Communicable disease and public health.

[9]  Hepatitis B vaccination for injection drug users--Pierce County, Washington, 2000. , 2001, MMWR. Morbidity and mortality weekly report.

[10]  S. Friedman,et al.  Behavioral risk reduction in a declining HIV epidemic: injection drug users in New York City, 1990-1997. , 2000, American journal of public health.

[11]  R. Heimer,et al.  Survival of HIV-1 in Syringes: Effects of Temperature during Storage , 2000, Substance use & misuse.

[12]  V. Dhopesh,et al.  Survey of Hepatitis B and C in Addiction Treatment Unit* , 2000, The American journal of drug and alcohol abuse.

[13]  A. Widell,et al.  Continued transmission of hepatitis B and C viruses, but no transmission of human immunodeficiency virus among intravenous drug users participating in a syringe/needle exchange program. , 2000, Scandinavian journal of infectious diseases.

[14]  L. Hoffer,et al.  HIV-1 transmission in injection paraphernalia: heating drug solutions may inactivate HIV-1. , 1999, Journal of acquired immune deficiency syndromes.

[15]  N. Weiss,et al.  Syringe exchange and risk of infection with hepatitis B and C viruses. , 1999, American journal of epidemiology.

[16]  S. Gore,et al.  Hepatitis B outbreak at Glenochil prison during January to June 1993 , 1998, Epidemiology and Infection.

[17]  L. Metsch,et al.  Parenteral transmission of HIV among injection drug users: assessing the frequency of multiperson use of needles, syringes, cookers, cotton, and water. , 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[18]  R Brookmeyer,et al.  Reductions in high-risk drug use behaviors among participants in the Baltimore needle exchange program. , 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[19]  C. Aitken,et al.  Incidence of bloodborne virus infection and risk behaviours in a cohort of injecting drug users in Victoria, 1990‐1995 , 1997, The Medical journal of Australia.

[20]  H. Margolis,et al.  Sequence-specific, single-primer amplification and detection of PCR products for identification of hepatitis viruses. , 1996, Journal of virological methods.

[21]  D. Vlahov,et al.  Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. , 1996, American journal of public health.

[22]  R. Heimer,et al.  Hepatitis in used syringes: the limits of sensitivity of techniques to detect hepatitis B virus (HBV) DNA, hepatitis C virus (HCV) RNA, and antibodies to HBV core and HCV antigens. , 1996, The Journal of infectious diseases.

[23]  D. Vlahov,et al.  Detection of HIV-1 DNA in needle/syringes, paraphernalia, and washes from shooting galleries in Miami: a preliminary laboratory report. , 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[24]  M. Alter,et al.  Reduced risk of hepatitis B and hepatitis C among injection drug users in the Tacoma syringe exchange program. , 1995, American journal of public health.

[25]  T. Rhodes,et al.  Changes in the injecting risk behaviour of injecting drug users in London, 1990‐1993 , 1995, AIDS.

[26]  B. Cookson,et al.  Survival of human immunodeficiency virus in suspension and dried onto surfaces , 1994, Journal of clinical microbiology.

[27]  T. Bell,et al.  An interview study of participants in the Tacoma, Washington, syringe exchange. , 1993, Addiction.

[28]  S. Hadler,et al.  Delta hepatitis: molecular biology and clinical and epidemiological features , 1993, Clinical Microbiology Reviews.

[29]  Alter Mj,et al.  Delta hepatitis and infection in North America. , 1993 .

[30]  M. Alter,et al.  Delta hepatitis and infection in North America. , 1993, Progress in clinical and biological research.

[31]  A. Perkins,et al.  An outbreak of hepatitis B among intravenous drug users in Medway. , 1988, Community medicine.

[32]  J. Devereux,et al.  A comprehensive set of sequence analysis programs for the VAX , 1984, Nucleic Acids Res..

[33]  M. Favero,et al.  SURVIVAL OF HEPATITIS B VIRUS AFTER DRYING AND STORAGE FOR ONE WEEK , 1981, The Lancet.